Metraipolis › archive › dc_23df2eb3b725
A review of evidence supporting amyloid beta reduction as a surrogate endpoint in Alzheimer's disease — Europe PMC PMID:41478826
- Source
- Europe PMC (en)
- Original
- https://europepmc.org/article/MED/41478826
- DOI
- 10.1016/j.tjpad.2025.100458
- License (as archived)
- solo-consultazione
- Archived
- 2026-11-07T05:45:28.414Z
- SHA-256 of the archived text
f77c23608f6d17a7a1b3153d4f5d9dbe3502ed41e61ee9e01d05d4efeb8be0ed- Stable URL of this page
https://metraipolis.com/documento/dc_23df2eb3b725
How to cite
A review of evidence supporting amyloid beta reduction as a surrogate endpoint in Alzheimer's disease — Europe PMC PMID:41478826 — Europe PMC (en), https://europepmc.org/article/MED/41478826 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_23df2eb3b725 (Metraipolis archive dc_23df2eb3b725, sha256 f77c23608f6d17a7a1b3153d4f5d9dbe3502ed41e61ee9e01d05d4efeb8be0ed)
BibTeX
@misc{dc23df2eb3b725,
title = {A review of evidence supporting amyloid beta reduction as a surrogate endpoint in Alzheimer's disease — Europe PMC PMID:41478826},
howpublished = {Europe PMC (en)},
url = {https://europepmc.org/article/MED/41478826},
note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_23df2eb3b725; sha256 f77c23608f6d17a7a1b3153d4f5d9dbe3502ed41e61ee9e01d05d4efeb8be0ed},
year = {2026}
}Archived text
The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/41478826. Agents can read the archived copy with the MCP tool read_document.